Proxima Clinical Research Announces Leadership Changes
Proxima, a specialized contract research organization (CRO) in the MedTech sector, has recently undergone a significant ownership transition. This strategic shift was highlighted in a statement from Billy Howell, Chairman of the Board, who expressed enthusiasm for the new phase in Proxima's journey.
Eric Ross Takes Charge as New CEO
As part of this transition, Eric Ross has been named the new Chief Executive Officer of Proxima. Ross brings a wealth of experience, having held numerous executive positions in various CRO and eclinical organizations. His leadership is expected to bolster Proxima’s efforts to assist MedTech and Biotech firms in achieving regulatory approvals while enhancing patient care outcomes.
Ross's Vision for Proxima
In his new role, Ross shared his excitement about joining Proxima at such a pivotal time for the industry. "I am honored to join the Proxima team during this significant period of change in the industry," he expressed. He emphasized Proxima’s reputation as a leader in MedTech, particularly in conducting clinical trials for devices and drugs, aided by an outstanding regulatory team that underpins clinical success. Moreover, Proxima has carved out a niche as the preferred CRO for AI-driven MedTech firms navigating the complex approval process.
Commitment to the Houston MedTech Community
Billy Howell, the Chairman of the Board, also expressed his excitement about the acquisition. He stated that, "Proxima's dedication to innovative MedTech creation over the years aligns perfectly with our vision for the Houston community." His commitment highlights the intent to nurture a dynamic ecosystem for MedTech innovation in Texas, fostering growth and collaboration among industry players.
Synergy with HGI Clinical
Howell's ownership extends beyond Proxima to include HGI Clinical, a CRO specializing in early-phase oncology and cell and gene therapy drug development. This strategic partnership is poised to strengthen the capabilities of both organizations, paving the way for accelerated advancements in medical technology.
Future Aspirations Under New Leadership
Commenting on his vision, Eric Ross indicated a proactive approach to collaboration within the company. He stated, "I look forward to working closely with the talented team at Proxima to accelerate our customers' path to approval and bring additional MedTech and Biotech solutions to patients." This statement reflects Ross’s commitment to enhancing the firm's offerings and supporting client success.
About Proxima Clinical Research
Founded in 2017, Proxima Clinical Research is a leading contract research organization offering regulatory, quality, and clinical research services. It operates from the Houston Texas Medical Center, known as the largest medical complex in the world. Proxima collaborates with diverse partners in the life sciences sector, including medical device manufacturers, pharmaceutical companies, biotechnologies, and diagnostic firms across 18 countries and five continents. The organization is incorporated as a Texas Corporation and is committed to furthering advancements in the industry.
Frequently Asked Questions
What is Proxima Clinical Research?
Proxima is a dedicated contract research organization specializing in MedTech, providing regulatory and clinical research support to a variety of life sciences companies.
Who is the new CEO of Proxima?
Eric Ross has been appointed as the new Chief Executive Officer, bringing extensive experience from previous executive roles in the CRO sector.
What is the focus of Proxima under Eric Ross's leadership?
Under Eric Ross's leadership, Proxima aims to accelerate the approval processes for MedTech and Biotech companies and improve patient outcomes through innovative solutions.
Where is Proxima located?
Proxima is headquartered in the Houston Texas Medical Center, the largest medical complex globally, which enhances its collaboration capabilities with medical innovators.
What other organizations does the Chairman of the Board manage?
Billy Howell also oversees HGI Clinical, which focuses on early-phase oncology and cell and gene therapy drug development, fostering synergies with Proxima.
